First 10 runs free
    Intelligence Feed event · Equity · 2026-11-07

    Axon falls 18% after Q3 miss on delayed $30M federal contract and FCF cut

    Question

    Axon falls 18% after Q3 miss on delayed $30M federal contract and FCF cut

    Direct answer

    Shares of Axon Enterprise sank 18% to a two-year low after reporting third-quarter results that lagged consensus expectations. The revenue shortfall was directly attributed to the postponement of a $30 million Federal Dedrone deployment. In addition to the top-line miss, the company cut its full-year free cash flow outlook and noted softer sales in its core Taser line. Management reiterated that the contract represents a postponement rather than a cancellation, asserting that underlying demand from law enforcement and federal customers remains healthy.

    Original publisher
    Market Ontology
    Evidence through
    2026-11-07
    Published
    2026-11-07
    Revision
    1 · 2026-11-07

    Cite as: Market Ontology, “Axon falls 18% after Q3 miss on delayed $30M federal contract and FCF cut”, revision 1, evidence through 2026-11-07. https://marketontology.com/market-events/2026-11-07/axon-falls-18-after-q3-miss-on-delayed-30m-federal-contract-and-fcf-cut-88bdaa

    EQUITY
    Axon falls 18% after Q3 miss on delayed $30M federal contract and FCF cut
    Shares of Axon Enterprise sank 18% to a two-year low after reporting third-quarter results that lagged consensus expectations. The revenue shortfall was directly attributed to the postponement of a $30 million Federal Dedrone deployment. In addition to the top-line miss, the company cut its full-year free cash flow outlook and noted softer sales in its core Taser line. Management reiterated that the contract represents a postponement rather than a cancellation, asserting that underlying demand from law enforcement and federal customers remains healthy.
    AXON
    Impact
    72
    YESTERDAY
    SIG
    85%
    AXON
    Axon falls 18% after Q3 miss on delayed $30M federal contract and FCF cut
    Shares of Axon Enterprise sank 18% to a two-year low after reporting third-quarter results that lagged consensus expectations. The revenue shortfall was directly attributed to the postponement of a $30 million Federal Dedrone deployment. In addition to the top-line miss, the company cut its full-year free cash flow outlook and noted softer sales in its core Taser line. Management reiterated that the contract represents a postponement rather than a cancellation, asserting that underlying demand from law enforcement and federal customers remains healthy.
    → A $30 million delay in federal contract revenue recognition cuts full-year free cash flow and triggers multiple de-rating across high-multiple defense tech equities.
    Impact
    Shares of Axon Enterprise sank 18% to a two-year low after reporting third-quarter results that lagged consensus expectations. The revenue shortfall was directly attributed to the postponement of a $30 million Federal Dedrone deployment. In addition to the top-line miss, the company cut its full-year free cash flow outlook and noted softer sales in its core Taser line. Management reiterated that the contract represents a postponement rather than a cancellation, asserting that underlying demand from law enforcement and federal customers remains healthy.
    Affected
    AXON
    Transmission
    A $30 million delay in federal contract revenue recognition cuts full-year free cash flow and triggers multiple de-rating across high-multiple defense tech equities.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    AXONfree cash flow multiple de-rating on federal procurement delaysDown1-4wAxon plunged 18% on a delayed $30 million Federal Dedrone deployment and cut FCF guidance.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    Find trades for this development

    Screen tradable expressions of this catalyst against your horizon and constraints. Nothing is submitted without your review.

    First 10 runs free

    First 10 runs free

    See today's live cards

    Public pages are published 24 hours after the product shows them. The product shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open live cards